Publications by authors named "David Hout"

Claim this Profile
2
27-gene Immuno-Oncology (IO) Score is Associated With Efficacy of Checkpoint Immunotherapy in Advanced NSCLC: A Retrospective BC Cancer Study.
David L Saltman, Matthew G Varga, Tyler J Nielsen, Nicole S Croteau, Heather M Lockyer, David R Hout

Clin Lung Cancer· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer.
Harsha Ranganath, Amit L Jain, Justin R Smith, Julie Ryder, Amina Chaudry, David R Hout

BMC Cancer· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic Chemotherapy.
Hiroko Masuda, Kenichi Harano, Sakiko Miura, Ying Wang, Yuko Hirota, David R Hout

JCO Precis Oncol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Novel Immunomodulatory 27-Gene Signature to Predict Response to Neoadjuvant Immunochemotherapy for Primary Triple-Negative Breast Cancer.
Toshiaki Iwase, Kim R M Blenman, Xiaotong Li, Emily Reisenbichler, Robert Seitz, David Hout

Cancers (Basel)· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of the tumor immune-microenvironment of adenocarcinoma of lung with a metastatic lesion in the pancreas treated successfully with first-line, single-agent pembrolizumab.
David L Saltman, Tyler J Nielsen, Davide Salina, David R Hout, Frank B McMahon

Ther Adv Med Oncol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel immuno-oncology algorithm measuring tumor microenvironment to predict response to immunotherapies.
Tyler J Nielsen, Brian Z Ring, Robert S Seitz, David R Hout, Brock L Schweitzer

Heliyon· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of triple-negative breast cancer cell lines classified under the same molecular subtype using different molecular characterization techniques: Implications for translational research.
Jose Rodrigo Espinosa Fernandez, Bedrich L Eckhardt, Jangsoon Lee, Bora Lim, Troy Pearson, David R Hout

PLoS One· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of molecular profile in triple-negative inflammatory and non-inflammatory breast cancer not of mesenchymal stem-like subtype.
Yohei Funakoshi, Ying Wang, Takashi Semba, Hiroko Masuda, David Hout

PLoS One· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rates of immune cell infiltration in patients with triple-negative breast cancer by molecular subtype.
Kenichi Harano, Ying Wang, Bora Lim, Robert S Seitz, Stephan W Morris, David R Hout

PLoS One· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Activity of Pembrolizumab in a Patient With Metastatic Triple-Negative Breast Cancer Without Tumor Programmed Death-Ligand 1 Expression: A Case Report and Correlative Biomarker Analysis.
Sajjad Bhatti, Jaimie Heldstab, Carolyn Lehn, Ossama Tawfik, Ryan M Ash, David R Hout

JCO Precis Oncol· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Performance of a RT-PCR Assay in Comparison to FISH and Immunohistochemistry for the Detection of ALK in Non-Small Cell Lung Cancer.
David R Hout, Brock L Schweitzer, Kasey Lawrence, Stephan W Morris, Tracy Tucker

Cancers (Basel)· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of triple-negative breast cancer molecular subtyping using RNA from matched fresh-frozen versus formalin-fixed paraffin-embedded tissue.
Bojana Jovanović, Quanhu Sheng, Robert S Seitz, Kasey D Lawrence, Stephan W Morris, David R Hout

BMC Cancer· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum to: Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients.
Brian Z Ring, David R Hout, Stephan W Morris, Kasey Lawrence, Brock L Schweitzer

BMC Cancer· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Successful treatment of hepatic oligometastases with stereotactic ablative radiotherapy and radiofrequency ablation in an anaplastic lymphoma kinase fusion-positive lung cancer patient.
Britta Weber, Mitchell Liu, Paul Sobkin, Stephan W Morris, David Hout

J Med Radiat Sci· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients.
Brian Z Ring, David R Hout, Stephan W Morris, Kasey Lawrence, Brock L Schweitzer

BMC Cancer· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detection of a TRAF1-ALK fusion in an anaplastic large cell lymphoma patient with chemotherapy and ALK inhibitor-resistant disease.
Kasey Lawrence, Brian Berry, John Handshoe, David Hout, Rosetta Mazzola

BMC Res Notes· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The host proteins transportin SR2/TNPO3 and cyclophilin A exert opposing effects on HIV-1 uncoating.
Vaibhav B Shah, Jiong Shi, David R Hout, Ilker Oztop, Lavanya Krishnan

J Virol· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A single amino acid substitution within the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein renders simian-human immunodeficiency virus (SHIV(KU-1bMC33)) susceptible to rimantadine.
David R Hout, Lisa M Gomez, Erik Pacyniak, Jean-Marie Miller, M Sarah Hill

Virology· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Substitution of the transmembrane domain of Vpu in simian-human immunodeficiency virus (SHIVKU1bMC33) with that of M2 of influenza A results in a virus that is sensitive to inhibitors of the M2 ion channel and is pathogenic for pig-tailed macaques.
David R Hout, Melissa L Gomez, Erik Pacyniak, Lisa M Gomez, Barbara Fegley

Virology· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Scrambling of the amino acids within the transmembrane domain of Vpu results in a simian-human immunodeficiency virus (SHIVTM) that is less pathogenic for pig-tailed macaques.
David R Hout, Melissa L Gomez, Erik Pacyniak, Lisa M Gomez, Sarah H Inbody

Virology· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of a region within the cytoplasmic domain of the subtype B Vpu protein of human immunodeficiency virus type 1 (HIV-1) that is responsible for retention in the golgi complex and its absence in the Vpu protein from a subtype C HIV-1.
Erik Pacyniak, Melissa L Gomez, Lisa M Gomez, Ellyn R Mulcahy, Mollie Jackson, David R Hout

AIDS Res Hum Retroviruses· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vpu-mediated CD4 down-regulation and degradation is conserved among highly divergent SIV(cpz) strains.
Lisa M Gomez, Erik Pacyniak, Melissa Flick, David R Hout, Melissa L Gomez

Virology· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vpu: a multifunctional protein that enhances the pathogenesis of human immunodeficiency virus type 1.
David R Hout, Ellyn R Mulcahy, Erik Pacyniak, Lisa M Gomez, Melissa L Gomez

Curr HIV Res· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fusion of the upstream vpu sequences to the env of simian human immunodeficiency virus (SHIV(KU-1bMC33)) results in the synthesis of two envelope precursor proteins, increased numbers of virus particles associated with the cell surface and is pathogenic for pig-tailed macaques.
David R Hout, Melissa L Gomez, Erik Pacyniak, Ellyn R Mulcahy, Lisa M Gomez

Virology· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The presence of the casein kinase II phosphorylation sites of Vpu enhances the CD4(+) T cell loss caused by the simian-human immunodeficiency virus SHIV(KU-lbMC33) in pig-tailed macaques.
Dinesh K Singh, Darcy M Griffin, Erik Pacyniak, Mollie Jackson, Michael J Werle, David R Hout

Virology· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis